Sydney, January 19, 2026, 17:29 AEDT — The market has closed.
- 4DMedical shares dropped roughly 4% on Monday following a choppy trading session.
- Placement shares are set to enter the market this week, prompting investors to prepare for a surge in stock availability.
- Attention turns to the U.S. launch of CT:VQ and the upcoming earnings report.
4DMedical Ltd shares dropped 4.3% on Monday, closing at A$4.86 after fluctuating between A$4.76 and A$5.42. The lung-imaging stock pulled back following a strong rally. An investor presentation was released in the morning, but the stock slipped by late afternoon.
Timing is key. 4DMedical is just days from closing a A$150 million institutional placement priced at A$3.80 per share, with the new shares set to start trading on January 22. The company said this capital raise, along with a related sale of existing shares, will boost its pro forma cash balance to over A$200 million. The funds will be used to advance its CT:VQ product in the US, where clinician interest has been described as “unprecedented.” Company Announcements
CT:VQ is a CT-based ventilation-perfusion scan that maps air and blood flow in the lungs. 4DMedical has targeted the U.S. as its primary growth market. This placement also marks a near-term technical milestone for traders: an increased float can quickly shift price dynamics, especially following a sharp run-up.
Founder and CEO Andreas Fouras expressed strong confidence during Monday’s investor webinar, describing the company’s U.S. pipeline as “unburstable momentum.” “The sky is the limit,” he declared, noting the technology could expand into “other places,” according to Stockhead. Stockhead
The broader market struggled, with the S&P/ASX 200 slipping 0.33% on Monday. Healthcare stocks took a hit, led by imaging software company Pro Medicus, which dropped 6.82%, according to Stockhead.
4DMedical’s placement structure is under scrutiny. The company confirmed the A$150 million deal involves both new shares and a “block trade” — an off-market sale of existing stock — with some shares coming from stock previously issued as collateral to Alpha Investment Partners. Importantly, 4DMedical said the proceeds from that block trade will go to the company, not Alpha.
MarketIndex groups 4DMedical with healthcare names like Nanosonics, Pro Medicus, and ResMed. However, it points out that no major broker covers 4DMedical in its consensus data. According to their calendar, the company’s next interim report is set for February 27.
That said, the near-term outlook is tricky. If the market can’t easily digest the new shares, the price might dip even without any negative fundamental updates. Execution risk remains a concern as well — hospital procurement cycles tend to drag, and revenue often comes in uneven chunks instead of a steady flow.
Traders will be eyeing the stock closely as placement shares begin trading on January 22, with the block trade settlement following on January 23. After those dates, the focus shifts to updates on U.S. customer adoption and the upcoming interim report scheduled for February 27.
